Industry news · event 2026-03-27 · 3 min read
The Additive Problem: 80%+ of Compounded GLP-1s Carry Extras — and a Novel Tirzepatide-B12 Adduct Surfaces (2026)
2026 analyses found the overwhelming majority of compounded GLP-1 weight-loss preparations spiked with B12 or amino acids — and identified a tirzepatide-B12 reaction product that exists in no approved drug.
GRGLP1ProviderCompare Research Team
Pricing & policy research
Quick answer2026 analyses found the overwhelming majority of compounded GLP-1 weight-loss preparations spiked with B12 or amino acids — and identified a tirzepatide-B12 reaction product that exists in no approved drug.
Two 2026 findings put numbers on the "personalization" era of compounded GLP-1s. First: by late 2025, more than 80% of compounded GLP-1 weight-loss preparations contained added ingredients — vitamin B12 and amino acids most commonly — additions that support the patient-specific legal theory but have no efficacy evidence at those doses. Second, and more pointed: analytical work identified a novel tirzepatide-B12 adduct — a reaction product of the peptide and the additive — present in mass-compounded product and present in no FDA-approved drug.
The chemistry lesson is the consumer lesson. An additive isn't inert scenery; peptides are reactive, formulation is a discipline, and "tirzepatide plus B12" can be a different molecule in the vial than either name implies. The FDA has been explicit that additives don't automatically create legitimate clinical difference — and this finding shows they can create unintended difference instead.
Our practical translation, unchanged but sharpened: the pharmacy is the product. Ask for the formulation, ask for a certificate of analysis, prefer programs that name their pharmacies — the diligence walked through in the 503A/503B guide.